• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Oramed Pharmaceuticals Inc.

    9/16/24 4:42:03 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORMP alert in real time by email
    SC 13G 1 ormp13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

     Oramed Pharmaceuticals, Inc.
    (Name of Issuer)
     
     Common Stock par value $0.012 per share
    (Title of Class of Securities)
     
    68403P203
    (CUSIP Number)
     
    September 10, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     2,048,634
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     2,048,634
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     2,048,634
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.0
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1(a). Name of Issuer:

     Oramed Pharmaceuticals Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     1185 Avenue of the Americas, Third Floor,

    New York, NY

    Item 2(a). Name of Person Filing:

      BML Investment Partners, L.P

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

     68403P203


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 
     2,048,634


    (b) Percent of class: 5.0


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote:0


    (ii) Shared power to vote or to direct the vote:
     2,048,634

      (iii) Sole power to dispose or to direct the disposition of:0

      (iv) Shared power to dispose or to direct the disposition of:
     2,048,634
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:September 16, 2024
     
     
    BML Captial Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     

    Get the next $ORMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORMP

    DatePrice TargetRatingAnalyst
    1/12/2023$30.00 → $3.00Buy → Hold
    Canaccord Genuity
    2/18/2022$20.00Overweight
    Cantor Fitzgerald
    11/30/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/29/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/2/2021$20.00 → $35.00Buy
    Aegis Capital
    7/29/2021$27.00 → $30.00Buy
    Canaccord Genuity
    More analyst ratings

    $ORMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

      Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

      JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.   The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Oramed Pharmaceuticals Issues Letter to Shareholders

      Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /

      3/4/25 9:00:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously

      1/12/23 7:54:45 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      2/18/22 6:43:35 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously

      11/30/21 7:36:11 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Financials

    Live finance-specific insights

    See more
    • Oramed Pharmaceuticals Issues Letter to Shareholders

      Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /

      3/4/25 9:00:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine

      NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.     Dear Shareholders, I'm excited to share with you significant milestones we have achieved over the past few months. Our oral delivery platform technology could apply to a range of proteins and disease modalities, and we expect over time to have a range of programs. We are currently advancing our two primary programs: oral insulin for diabetes and an oral COVID vaccine. We believe t

      5/25/21 8:40:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Leadership Updates

    Live Leadership Updates

    See more
    • Oramed Appoints Ben Shapiro to its Board of Directors

      NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.     Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned

      5/1/23 4:45:00 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

      NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board. Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes progra

      6/1/22 7:55:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oramed Pharmaceuticals Appoints Chief Legal Officer

      NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors. "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer. Netanel's business-minded approach, legal acumen and strong operational skills will be instrumental to Oramed

      12/8/21 7:30:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    SEC Filings

    See more
    • Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      4/28/25 4:30:31 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Oramed Pharmaceuticals Inc.

      10-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      3/27/25 5:00:24 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      3/3/25 4:30:09 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Kidron Miriam was granted 192,667 shares, increasing direct ownership by 19% to 1,193,333 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      2/11/25 4:31:37 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO & CBO Hexter Joshua was granted 126,834 shares, increasing direct ownership by 18% to 833,167 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      2/11/25 4:31:21 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Kidron Nadav was granted 427,000 shares, increasing direct ownership by 19% to 2,686,598 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      2/11/25 4:31:05 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oramed Pharmaceuticals Inc.

      SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

      9/16/24 4:42:03 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Oramed Pharmaceuticals Inc.

      SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

      3/22/24 9:30:27 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Oramed Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

      9/2/21 4:49:56 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care